Skip to main content
Signal8

BriaCell Therapeutics Corp. (BCTXL)

BriaCell Therapeutics Corp. is a clinical-stage biotechnology company, which engages in the development of novel immunotherapies to transform cancer care. It currently advancing its Bria-IMT™ targeted immunotherapy in combination with an immune check point inhibitor in a pivotal 1 Phase 3 study in metastatic breast cancer. The company was founded by Charles L. Wiseman and Isaac Benjamin Maresky on July 26, 2006 and is headquartered in West Vancouver, Canada.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

BriaCell Therapeutics Corp. logo

BriaCell Therapeutics Corp.

NASDAQ:BCTXLSub-class of BCTXHealthcare
-2.44%$0.8000
CLOSED
Mkt Cap$6.99M
EV-
Float8.72M
O/S8.73M
VOL79K sh
$ Vol$63K
RVOL4.64×
Inst Own-
SI0.1%
Net Cash/Sh-
Dilution
BriaCell Therapeutics Corp. logoNASDAQ:BCTXLClosed$0.8000-2.44%
Financials Summary

No financial data available.

Debt & Equity

No debt & equity data available.

Shares Outstanding
Short Interest

No short interest data available.

Split History

No splits on record

Nothing in BCTXL's public trading history: no forward or reverse split has affected the share count.

Balance Sheet Details

No balance sheet details available.

Income Statement

No income statement data available.

Balance Sheet

No balance sheet data available.

Cash Flow Statement

No cash flow data available.